Literature DB >> 16839508

Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides.

Ora Shovman1, Boris Gilburd, Gisele Zandman-Goddard, Yaniv Sherer, Yehuda Shoenfeld.   

Abstract

Within the last year, a growing body of evidence for a distinct role of antineutrophil cytoplasmic antibodies (ANCA) in the pathogenesis of ANCA-associated vasculitides (AAV) has developed. An experimental model of myeloperoxidase (MPO)-ANCA-associated vasculitis provided direct and convincing in vivo evidence that MPO-ANCA are primary pathogenic factors in small-vessel vasculitis by augmenting of leukocyte-vessel wall interaction and leukocyte-mediated vascular injury. Determination of bacterial lipopolysaccharide (LPS) effects on disease severity in a mouse model of anti-MPO-induced glomerulonephritis showed that ANCA and other proinflammatory stimuli of infectious origin acted in synergism in the development of destructive inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16839508     DOI: 10.1007/s11926-006-0012-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  54 in total

1.  Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.

Authors:  J-S F Sanders; M G Huitma; C G M Kallenberg; C A Stegeman
Journal:  Rheumatology (Oxford)       Date:  2006-01-06       Impact factor: 7.580

Review 2.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 3.  Infections and SLE.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Autoimmunity       Date:  2005-11       Impact factor: 2.815

4.  Antimyeloperoxidase antibodies in the Churg-Strauss syndrome.

Authors:  J W Tervaert; R Goldschmeding; J D Elema; A E von dem Borne; C G Kallenberg
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

5.  Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation.

Authors:  Katja Hattar; Sandra van Bürck; Annette Bickenbach; Ulrich Grandel; Ulrich Maus; Jürgen Lohmeyer; Elena Csernok; Thomas Hartung; Werner Seeger; Friedrich Grimminger; Ulf Sibelius
Journal:  J Leukoc Biol       Date:  2005-07-08       Impact factor: 4.962

6.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.

Authors:  R J Falk; S Hogan; T S Carey; J C Jennette
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

7.  Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

Authors:  Dennis Huugen; Hong Xiao; Anita van Esch; Ronald J Falk; Carine J Peutz-Kootstra; Wim A Buurman; Jan Willem Cohen Tervaert; J Charles Jennette; Peter Heeringa
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

Review 8.  The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions.

Authors:  E R Popa; J W Cohen Tervaert
Journal:  Intern Med       Date:  2003-09       Impact factor: 1.271

9.  Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo.

Authors:  E Csernok; M Ernst; W Schmitt; D F Bainton; W L Gross
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

10.  Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.

Authors:  Heiko Pfister; Markus Ollert; Leopold F Fröhlich; Leticia Quintanilla-Martinez; Thomas V Colby; Ulrich Specks; Dieter E Jenne
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

View more
  5 in total

1.  Is rituximab superior to cyclophosphamide for ANCA-associated vasculitis for induction of remission, and with a better safety profile?

Authors:  Ignacio Garcia-Valladares; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

2.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 3.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Steroid-responsive encephalopathy: an under recognised aspect of Hashimoto's thyroiditis.

Authors:  Tanawan Riangwiwat; Jutarat Sangtian; Chutintorn Sriphrapradang
Journal:  BMJ Case Rep       Date:  2015-03-12

Review 5.  Vasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment.

Authors:  Kjell Tullus; Stephen D Marks
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.